Revelation Biosciences (REVB)
NASDAQ:REVB
Want to see REVB full AI Analyst Report?
REVB Stock Chart & Stats
$0.90
-$0.04(-6.62%)
At close: 4:00 PM EST
$0.90
-$0.04(-6.62%)
Day’s Range― - ―
52-Week Range$0.88 - $12.88
Previous CloseN/A
Volume326.26K
Average Volume (3M)740.56K
Market Cap
$3.89M
Enterprise Value-$9.07M
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$759.04K
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 07, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.14
Shares Outstanding3,908,420
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-2.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.26K
Enterprise Value/Ebitda0.90
Forecast
1Y Price Target
$16.00Price Target Upside1677.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage & Higher EquityLow debt and a materially larger equity base reduce refinancing pressure and lengthen the development runway. This capital structure gives management durable flexibility to fund multi-quarter clinical programs and absorb R&D volatility without immediate debt-servicing constraints.
Warrant-related Financing FlexibilityStockholder approval clarifies warrant mechanics and extends procedural authority to issue underlying shares, creating a structural avenue for future equity-linked financing. That confirmed mechanism supports predictable access to capital over multiple years for clinical development needs.
Focused Immunology PipelineA targeted platform in innate immunity and intranasal delivery creates a defensible niche versus broader biotech pipelines. Specialization can improve clinical design efficiency, attract strategic partners, and sustain long-term value creation if lead programs advance through pivotal stages.
Bears Say
No Revenue, Widening LossesBeing pre-revenue with sizable and widening net losses means the business lacks commercial cash flow and remains valuation-dependent on trial outcomes. This structural deficit forces reliance on capital markets and lengthens the path to self-sustaining operations absent successful commercialization.
Sustained Cash BurnPersistent negative operating and free cash flow, despite year-over-year improvement, constrains strategic optionality. Ongoing burn increases the probability of future dilution or restrictive financing, limits ability to scale trials independently, and pressures near-to-medium term resource allocation.
Very Small Operating ScaleA headcount of eight implies limited internal capacity to run concurrent trials, regulatory work, and commercialization planning. Heavy reliance on CROs and partners can slow execution, raise per-program costs, and introduce coordination risk that affects durable program timelines and control.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $0.88 and its highest was $12.88 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $3.89M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is Aug 07, 2026 which is in 53 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on May 07, 2026. The company reported -$2.71 earnings per share for the quarter, the consensus estimate of -$2.71 by $0.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Undervalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -0.83.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 3,908,420 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$2.71 in its last earnings report, expectations of -$2.71. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
REVB Stock 12 Month Forecast
Average Price Target
$16.00
▲(1677.78% Upside)
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
8.82% Insiders
0.69% Mutual Funds
10.81% Other Institutional Investors
79.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---